Barclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4
Barclays analyst Glen Santangelo maintains GoodRx Holdings (NASDAQ:GDRX) with a Underweight and raises the price target from $3 to $4.
Read original at benzingaStocks · News reference
GoodRx Holdings Raises FY2026 Sales Guidance from $765.000M-$785.000M to $790.000M-$805.000M vs $775.751M Est
GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $765.000 million-$785.000 million to $790.000 million-$805.000 million vs $775.751 million estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 8:38 PM
- Checked
- Aug 5, 2026, 8:38 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.
Read original at benzingaCitigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.
Read original at benzingaTD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5
TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.
Read original at benzinga